Allarity Therapeutics extends Nasdaq compliance deadline until May 14, 2024, with a strategic plan of cost-cutting and capital raising.
Allarity Therapeutics, a pharma firm focused on personalized cancer treatments, obtained a Nasdaq extension until May 14, 2024, to regain compliance with Listing Rule 5550(b)(1). The company presented a strategic plan detailing cost-cutting measures and capital raising efforts to meet the $2.5 million equity requirement. Allarity has already initiated a 1-for-20 reverse stock split and reduced monthly operational expenditures.
April 17, 2024
3 Articles